American Pharmacogenomics Association (APGxA)
The American Pharmacogenomics Association (APGxA) provides an exclusive platform for PGx leaders to connect, collaborate, and leverage the commercial opportunities within this rapidly evolving field. APGxA members gain access to invaluable resources, insights, and networking opportunities that drive business growth and success. Join APGxA and position your organization at the forefront of personalized medicine.
Sign up for our Community Pop-Up PGx Screening!
Get the Right Meds for YOU: A Year-Long Ten City Tour of DNA Medication Screening
The American Pharmacogenomics Association (APGxA) is a driving force in the burgeoning field of pharmacogenomics, bridging the gap between genetic insights and practical healthcare solutions. APGxA serves as a central hub for industry professionals, fostering collaboration, education, and research to accelerate the integration of pharmacogenomics into mainstream clinical practice.
Beyond its core activities, APGxA actively engages in public outreach and advocacy, partnering with key stakeholders to champion the adoption of pharmacogenomic testing. By equipping healthcare providers and patients with the knowledge and tools to interpret genetic data, APGxA empowers informed decision-making and paves the way for personalized treatment plans.
With its additional International division, APGxA extends its reach globally, promoting awareness and facilitating the adoption of pharmacogenomics worldwide. Through its multifaceted efforts, APGxA is catalyzing the transformation of healthcare, enabling more personalized, effective, and safer drug therapies tailored to each patient’s unique genetic profile.
What we have to offer…
Membership Benefits
ADVOCACY, not mentioned to the list on the right because there is simply too much to say about it.
The American Pharmacogenomics Association (APGxA) is a catalyst for business growth in the pharmacogenomics sector, providing invaluable support to a wide range of professionals, from labs and pharmacists to researchers and billing specialists. APGxA equips its members with the knowledge, resources, and networking opportunities needed to thrive in this rapidly evolving field. By fostering collaboration, innovation, and education, APGxA is driving the growth of the pharmacogenomics market, creating new business opportunities, and ultimately improving patient care through personalized medicine.
The American Pharmacogenomics Association proudly partners with the Western New England University College of Pharmacy’s Master of Science in Pharmacogenomics program. Taught in the cutting-edge facilities of the Center for the Science and Pharmacy, the curriculum equips students for careers in research, the pharmaceutical sector, regulatory bodies, genetic testing labs, or clinical environments. This program offers a comprehensive foundation for those seeking to advance in the field of pharmacogenomics.
Our Webinar Series. Unmatched.
What You Need to Know About PGx Panels and PGx Reporting
Date: First Quarter 2026
Time: 9:00AM PST
Ruben Bonilla Guerrero, MD, FACMG, FADLM, MB (ASCP), CGMBS, CEO of Genetica Consulting Services will be presenting a webinar on the topic of PGx panels and PGx reporting.
2026 Summit
Date: TBA
Time: TBA
As the pharmacogenomics industry races toward a staggering $50 billion valuation, the 2026 Summit emerges as the definitive catalyst where visionary leaders shape tomorrow’s healthcare landscape.
This isn’t just another conference. It’s the epicenter where pioneering business executives and trailblazing educators collide to unlock unprecedented market opportunities in pharmacogenomics. Prepare to witness breakthrough innovations, forge game-changing partnerships, and discover how genetic insights are revolutionizing patient care on a global scale.
… Or Take Our Popular PGx Certificate Course
Pharmacogenomics: Understanding Genetic Influences on Drug Response
This course on Pharmacogenomics delves into the intricate relationship between genetic variations and drug responses, tackling the pressing issue of optimizing medication efficacy and minimizing adverse reactions. Click the button to get more information …
Grab a cup and join us for our popular live bi-monthly PGx Coffee Chat
Next one: October 15, 2025 at 7:30am PST (every other third Wednesday).
Our Curated eBook Library
Education will remain one of our primary goals. The American Pharmacogenomics Association (APGxA) prioritizes education as a cornerstone of its mission. By empowering patients and healthcare professionals with knowledge about PGx testing, APGxA strives to bridge the gap between scientific advancements and real-world application. individuals to make informed decisions about their medications, while also equipping healthcare providers with the tools to integrate PGx into personalized treatment plans. Ultimately, APGxA’s educational initiatives pave the way for a future of optimized medication management and improved patient outcomes.
Our Published Content Curated Just for You
Lydia Kariuki has been named Managing Editor of the APGxA popular published business content blog. Her writing history goes deep with the Founder, almost 20 years back. Lydia will be covering recent studies in the space as short-form blogs, and share relevant market news where it makes sense. She will also soon facilitate 30-minute interview with key contributors to the Pharmacogenomics space.
Lydia Kariuki
Managing Editor
Lydia@apgxa.com
[{"id":7627,"link":"https:\/\/americanpharmacogenomicsassociation.com\/education\/machine-learning-for-pharmacogenomic-variant-effect-predictions-insights-from-a-recent-review\/","name":"machine-learning-for-pharmacogenomic-variant-effect-predictions-insights-from-a-recent-review","thumbnail":{"url":"https:\/\/americanpharmacogenomicsassociation.com\/wp-content\/uploads\/2025\/12\/ML.avif","alt":"Machine Learning for pharmacogenomic variant effect predictions: Insights From a Recent Review"},"title":"Machine Learning for pharmacogenomic variant effect predictions: Insights From a Recent Review","postMeta":{"_edit_lock":["1764860222:167"],"rank_math_internal_links_processed":["1"],"_thumbnail_id":["7628"],"_edit_last":["167"],"sib_push_meta_box_present":[""],"sib_push_send_notification":[""],"sib_push_last_notification_content":["Machine Learning for pharmacogenomic variant effect predictions: Insights From a Recent Review"],"sib_push_last_notification_timestamp":["1764831413"],"sib_push_send_notification_delay_seconds":["0"],"sib_push_target_tags":[null],"sib_push_target_segment_ids":["@ALL"],"sib_push_target_brevo_segment_ids":[null],"sib_push_target_brevo_list_ids":[null],"sib_push_utm_source":[null],"sib_push_utm_medium":[null],"sib_push_utm_campaign":[null],"sib_push_utm_term":[null],"sib_push_utm_content":[null],"_mepr_unauthorized_message_type":["default"],"_mepr_unauthorized_message":[""],"_mepr_unauth_login":["default"],"_mepr_unauth_excerpt_type":["default"],"_mepr_unauth_excerpt_size":["100"],"_std_metabox_details":["a:2:{s:5:\"delay\";s:0:\"\";s:10:\"form_alias\";s:0:\"\";}"],"_learndash_course_grid_short_description":[""],"_post":["a:2:{i:0;s:0:\"\";s:29:\"post_course_short_description\";s:0:\"\";}"],"_learndash_course_grid_duration":[""],"_learndash_course_grid_enable_video_preview":["0"],"_learndash_course_grid_video_embed_code":[""],"_learndash_course_grid_custom_button_text":[""],"_learndash_course_grid_custom_ribbon_text":[""]},"author":{"name":"Lydia Kariuki","link":"https:\/\/americanpharmacogenomicsassociation.com\/author\/lkariuki\/"},"date":"Dec 4, 2025","dateGMT":"2025-12-04 14:56:50","modifiedDate":"2025-12-04 06:56:53","modifiedDateGMT":"2025-12-04 14:56:53","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/education\/\" rel=\"category tag\">Education<\/a>","space":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/education\/\" rel=\"category tag\">Education<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/drug-metabolism\/' rel='post_tag'>Drug Metabolism<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/genetic-testing\/' rel='post_tag'>Genetic Testing<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/personalized-medicine\/' rel='post_tag'>personalized medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pgx\/' rel='post_tag'>pgx<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pharmacogenetic-testing\/' rel='post_tag'>Pharmacogenetic testing<\/a>"},"readTime":{"min":7,"sec":22},"status":"publish","excerpt":""},{"id":7623,"link":"https:\/\/americanpharmacogenomicsassociation.com\/research\/rethinking-pharmacogenomics-with-multi-omics-and-ai\/","name":"rethinking-pharmacogenomics-with-multi-omics-and-ai","thumbnail":{"url":"https:\/\/americanpharmacogenomicsassociation.com\/wp-content\/uploads\/2025\/12\/3947a4e3-2001-4a3b-8ae5-f03cfd81cd08-e1764696255742.avif","alt":"Rethinking Pharmacogenomics with Multi-Omics and AI"},"title":"Rethinking Pharmacogenomics with Multi-Omics and AI","postMeta":{"_edit_lock":["1764696372:167"],"rank_math_internal_links_processed":["1"],"_thumbnail_id":["7624"],"_edit_last":["167"],"sib_push_meta_box_present":[""],"sib_push_send_notification":[""],"sib_push_last_notification_content":["Rethinking Pharmacogenomics with Multi-Omics and AI"],"sib_push_last_notification_timestamp":["1764667562"],"sib_push_send_notification_delay_seconds":["0"],"sib_push_target_tags":[null],"sib_push_target_segment_ids":["@ALL"],"sib_push_target_brevo_segment_ids":[null],"sib_push_target_brevo_list_ids":[null],"sib_push_utm_source":[null],"sib_push_utm_medium":[null],"sib_push_utm_campaign":[null],"sib_push_utm_term":[null],"sib_push_utm_content":[null],"_mepr_unauthorized_message_type":["default"],"_mepr_unauthorized_message":[""],"_mepr_unauth_login":["default"],"_mepr_unauth_excerpt_type":["default"],"_mepr_unauth_excerpt_size":["100"],"_std_metabox_details":["a:2:{s:5:\"delay\";s:0:\"\";s:10:\"form_alias\";s:0:\"\";}"],"_learndash_course_grid_short_description":[""],"_post":["a:2:{i:0;s:0:\"\";s:29:\"post_course_short_description\";s:0:\"\";}"],"_learndash_course_grid_duration":[""],"_learndash_course_grid_enable_video_preview":["0"],"_learndash_course_grid_video_embed_code":[""],"_learndash_course_grid_custom_button_text":[""],"_learndash_course_grid_custom_ribbon_text":[""]},"author":{"name":"Lydia Kariuki","link":"https:\/\/americanpharmacogenomicsassociation.com\/author\/lkariuki\/"},"date":"Dec 2, 2025","dateGMT":"2025-12-02 17:25:58","modifiedDate":"2025-12-02 09:26:02","modifiedDateGMT":"2025-12-02 17:26:02","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/research\/\" rel=\"category tag\">Research<\/a>","space":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/research\/\" rel=\"category tag\">Research<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/genomic-medicine\/' rel='post_tag'>Genomic Medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/healthcare-innovation\/' rel='post_tag'>Healthcare innovation<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pharmacogenetic-testing\/' rel='post_tag'>Pharmacogenetic testing<\/a>"},"readTime":{"min":2,"sec":15},"status":"publish","excerpt":""},{"id":7599,"link":"https:\/\/americanpharmacogenomicsassociation.com\/business\/vega-sirius-the-future-of-pharmacogenomics\/","name":"vega-sirius-the-future-of-pharmacogenomics","thumbnail":{"url":"https:\/\/americanpharmacogenomicsassociation.com\/wp-content\/uploads\/2025\/11\/vega.avif","alt":""},"title":"Vega, Sirius, &The Future of Pharmacogenomics","postMeta":{"_edit_lock":["1763640705:167"],"rank_math_internal_links_processed":["1"],"_thumbnail_id":["7600"],"_edit_last":["167"],"sib_push_meta_box_present":["1"],"sib_push_send_notification":["0"],"sib_push_last_notification_content":["Vega, Sirius &The Future of Pharmacogenomics"],"sib_push_last_notification_timestamp":["1763611787"],"sib_push_send_notification_delay_seconds":["0"],"sib_push_target_tags":[null],"sib_push_target_segment_ids":["@ALL"],"sib_push_target_brevo_segment_ids":[null],"sib_push_target_brevo_list_ids":[null],"sib_push_utm_source":[null],"sib_push_utm_medium":[null],"sib_push_utm_campaign":[null],"sib_push_utm_term":[null],"sib_push_utm_content":[null],"_mepr_unauthorized_message_type":["default"],"_mepr_unauthorized_message":[""],"_mepr_unauth_login":["default"],"_mepr_unauth_excerpt_type":["default"],"_mepr_unauth_excerpt_size":["100"],"_std_metabox_details":["a:2:{s:5:\"delay\";s:0:\"\";s:10:\"form_alias\";s:0:\"\";}"],"_learndash_course_grid_short_description":[""],"_post":["a:2:{i:0;s:0:\"\";s:29:\"post_course_short_description\";s:0:\"\";}"],"_learndash_course_grid_duration":[""],"_learndash_course_grid_enable_video_preview":["0"],"_learndash_course_grid_video_embed_code":[""],"_learndash_course_grid_custom_button_text":[""],"_learndash_course_grid_custom_ribbon_text":[""]},"author":{"name":"Lydia Kariuki","link":"https:\/\/americanpharmacogenomicsassociation.com\/author\/lkariuki\/"},"date":"Nov 20, 2025","dateGMT":"2025-11-20 12:09:44","modifiedDate":"2025-11-20 04:11:38","modifiedDateGMT":"2025-11-20 12:11:38","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/business\/\" rel=\"category tag\">Business<\/a>","space":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/business\/\" rel=\"category tag\">Business<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/genomic-medicine\/' rel='post_tag'>Genomic Medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/personalized-medicine\/' rel='post_tag'>personalized medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pharmacogenetic-testing\/' rel='post_tag'>Pharmacogenetic testing<\/a>"},"readTime":{"min":2,"sec":32},"status":"publish","excerpt":""},{"id":7583,"link":"https:\/\/americanpharmacogenomicsassociation.com\/business\/oneome-to-shutdown-deal-a-blow-to-pgx-industry-momentum\/","name":"oneome-to-shutdown-deal-a-blow-to-pgx-industry-momentum","thumbnail":{"url":"https:\/\/americanpharmacogenomicsassociation.com\/wp-content\/uploads\/2025\/11\/oneome.avif","alt":"OneOme to Shutdown, Deal a Blow to PGx Industry Momentum"},"title":"OneOme to Shutdown, Deal a Blow to PGx Industry Momentum","postMeta":{"_edit_lock":["1763057567:167"],"rank_math_internal_links_processed":["1"],"_thumbnail_id":["7584"],"_edit_last":["167"],"sib_push_meta_box_present":["1"],"sib_push_send_notification":["0"],"sib_push_last_notification_content":["OneOme to Shutdown, Deal a Blow to PGx Industry Momentum"],"sib_push_last_notification_timestamp":["1763028262"],"sib_push_send_notification_delay_seconds":["0"],"sib_push_target_tags":[null],"sib_push_target_segment_ids":["@ALL"],"sib_push_target_brevo_segment_ids":[null],"sib_push_target_brevo_list_ids":[null],"sib_push_utm_source":[null],"sib_push_utm_medium":[null],"sib_push_utm_campaign":[null],"sib_push_utm_term":[null],"sib_push_utm_content":[null],"_mepr_unauthorized_message_type":["default"],"_mepr_unauthorized_message":[""],"_mepr_unauth_login":["default"],"_mepr_unauth_excerpt_type":["default"],"_mepr_unauth_excerpt_size":["100"],"_std_metabox_details":["a:2:{s:5:\"delay\";s:0:\"\";s:10:\"form_alias\";s:0:\"\";}"],"_learndash_course_grid_short_description":[""],"_post":["a:2:{i:0;s:0:\"\";s:29:\"post_course_short_description\";s:0:\"\";}"],"_learndash_course_grid_duration":[""],"_learndash_course_grid_enable_video_preview":["0"],"_learndash_course_grid_video_embed_code":[""],"_learndash_course_grid_custom_button_text":[""],"_learndash_course_grid_custom_ribbon_text":[""]},"author":{"name":"Lydia Kariuki","link":"https:\/\/americanpharmacogenomicsassociation.com\/author\/lkariuki\/"},"date":"Nov 13, 2025","dateGMT":"2025-11-13 18:04:18","modifiedDate":"2025-11-13 10:12:39","modifiedDateGMT":"2025-11-13 18:12:39","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/business\/\" rel=\"category tag\">Business<\/a>","space":"<a href=\"https:\/\/americanpharmacogenomicsassociation.com\/category\/business\/\" rel=\"category tag\">Business<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/genomic-medicine\/' rel='post_tag'>Genomic Medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/personalized-medicine\/' rel='post_tag'>personalized medicine<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pgx\/' rel='post_tag'>pgx<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/pharmacogenetic-testing\/' rel='post_tag'>Pharmacogenetic testing<\/a><a href='https:\/\/americanpharmacogenomicsassociation.com\/tag\/precision-medicine\/' rel='post_tag'>Precision Medicine<\/a>"},"readTime":{"min":2,"sec":0},"status":"publish","excerpt":""}]
legislation
We support Bill H.R. 6875 – 17th Congress (2022)
Sponsored by Representative, Eric Swalwell, this bill sets out requirements and activities to address adverse drug events, including using pharmacogenomic testing to prevent them. (Pharmacogenomic testing uses a patient’s genetic information to help determine the safety, efficacy, and dosage of medications for treatments.)
A proud handful of our member companies…
